Atossa Genetics (NASDAQ:ATOS) and Titan Medical (NASDAQ:TMDI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.
Earnings & Valuation
This table compares Atossa Genetics and Titan Medical’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Atossa Genetics||N/A||N/A||-$11.40 million||($5.50)||-0.40|
This is a summary of recent ratings and target prices for Atossa Genetics and Titan Medical, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Atossa Genetics presently has a consensus price target of $9.00, suggesting a potential upside of 307.24%. Titan Medical has a consensus price target of $6.67, suggesting a potential upside of 193.69%. Given Atossa Genetics’ higher possible upside, research analysts plainly believe Atossa Genetics is more favorable than Titan Medical.
This table compares Atossa Genetics and Titan Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
3.2% of Atossa Genetics shares are held by institutional investors. Comparatively, 13.1% of Titan Medical shares are held by institutional investors. 3.3% of Atossa Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Titan Medical beats Atossa Genetics on 5 of the 8 factors compared between the two stocks.
About Atossa Genetics
Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.
About Titan Medical
Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.